Enhertu approved in EU for HER2-low breast cancer
The European Commission has approved Enhertu in the EU as the first HER2-directed therapy for patients with HER2-low metastatic breast cancer.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed
